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Discussion
Dr Frank Sellke (Boston, Mass). I noticed for several of the param-
eters you looked at, in particular endothelial-dependent relaxation,
Hcort itself really didn’t have any effect, but when you added it to
CyA, it seemed to aggravate the detrimental effects. Why do you
see this added detrimental action of Hcort when by itself doesn’t
cause any impaired effect?
Dr Ramzy. When we looked at endothelial-dependent vasore-
laxation, we did not see a significant difference. There are 2 sides
to NO production: There is the expression of eNOS and the activity
of eNOS. Because of time constraints I did not show all our data.
CyA has direct inhibitory effects on eNOS in addition to its ability
to decrease its expression, whereas Hcort demonstrated decreased
expression with no change in activity. Thus, when we looked at en-
dothelial-dependent vasorelaxation, we did not find any significant
differences with Hcort. However, when we looked at Hcort’s effect
on sensitivity to ET-1, there was significantly aggravated ET-1–in-
duced vasospasm because it has the ability to up-regulate the ETA
receptor, which is made even worse when we add CyA. When we
combined the 2, the expression of eNOS is significantly decreased
compared with CyA alone. With the added effect of CyA directly
inhibiting eNOS activity, we end up with worsening endothelial
dysfunction.
DrChadwick Stouffer (Grand Rapids, Mich). In your 4 groups,
it looked like your ET-1 levels were all comparable. Can you com-
ment on your conclusion that that did affect homeostasis? How did
you look at the oxygen-free radical production in the CyA group?
Dr Ramzy. When we looked at the figure for ET-1 production,
the levels were the same in our 3 main groups. However, in a situa-
tion of decreased NO production (again, because of the time con-
straint I did not demonstrate these data), our 3 main groups
impaired NO production. Under normal conditions with an inhibi-
tion of NO production, ET-1 levels should decrease. Therefore,
maintaining ET-1 levels at control levels is actually a relative in-
crease in ET-1; therefore, at those levels it was a relative elevation
of ET-1 compared with our control group. We measured ET-1 levels
at the same time we determined our trough levels for CyA, and sev-
eral studies have demonstrated that CyA on its own increases ET-1
levels in a concentration-dependent manner. As CyA levels change,
ET-1 production changes. Therefore, if we measure ET-1 levels at
peak concentration, I suspect we will see higher levels. Dr Takeda’s
group demonstrated that 6 weeks of CyA treatment elevated levels
of ET-1.
In addition to our data demonstrating free-radical injury, we also
looked at a cell culture model whether these drugs are able to pro-
duce free radicals, and CyA, as seen here, has the ability to increase
free-radical production compared with control.
Dr Mark Krasna (Towson, Md). Dr Ramzy, perhaps you could
just elaborate a little bit then on the possible modifications in treat-
ment strategies that you would use now?
Dr Ramzy. We actually performed additional studies looking at
whether our theories would actually work. Tetrahydrobiopterin
(BH4) is an essential cofactor for eNOS, and when we give this to
our CyA treatment group we do see a restoration to near normal
of vasomotor function in terms of endothelial-dependent vasorelax-
ation with BH4, demonstrating the importance of eNOS dimeriza-
tion. Therefore, CyA not only decreases eNOS expression but
also results in uncoupling of the enzyme, which produces more
free radicals than NO. The addition of Bosentan, an ET-1 antagonist,
completely restores endothelial-dependent vasorelaxation, and sim-
ilarly with endothelial-independent vasorelaxation, BH4 has the
ability to attenuate CyA effects. As you can see in this figure, there
is still a lag, indicating the NO side of the equation is not the only
player, that there is, in addition to NO impairment, another factor,
which our data suggest is ET-1. Thus, we believe that optimal ther-
apy should consist of both eNOS augmentation and ET-1 blockade.
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